So it’s been a few years since we last spoke. Let’s start with a brief overview and history of the company. Mr. Itescu: Sure. So Mesoblast has been publicly listed both on Nasdaq and the Australian ...

Recently you wrote a wonderful article that was published in Forbes magazine. In the context of an introduction to your coverage, what inspired you to write that piece, and what are some of the main ...

We’ve spoken several times before, but can you just give our readers a brief refresher on the company and how it has evolved over the years? Mr. Do: BioVie is a biotech company that started developing ...

Matt Phipps, Ph.D., is Group Head of Biotechnology Equity Research at William Blair & Co, LLC. He joined the firm in November 2014, after working as a postdoctoral research fellow at Texas Scottish ...

Interview with Ryan Zimmerman, Managing Director and Medical Technology Analyst, BTIG and former Director of Surgery at ...

Tell us briefly about Picard Medical and the history of SynCardia Total Artificial Heart. Mr. Schnegelsberg: Let me start with SynCardia and then go to Picard. SynCardia is a company with a long ...

For readers who are not familiar with SINTX, give us a brief overview of the company and how it evolved into what it is today. Mr. Olson: SINTX was founded on the use of silicon nitride ceramic ...

In the context of an introduction to your coverage, could you define the life sciences space, and discuss how it differs from the biotech or medtech space? Ms. Utterback: The life science companies ...

For readers who may just be hearing about HeartBeam, explain to us what clinical problem you are trying to solve and why hasn’t that been able to be solved with existing cardiac monitoring tools? Mr.

In the context of an introduction to your coverage, how do you evaluate names in the medtech space? Mr. Zimmerman: The lens we look through is consistency of execution, whether internal expectations ...

For readers who are not familiar with Butterfly Network, give us a short introduction. What problem are you solving, and why does ultrasound-on-chip matter clinically and economically? Mr. DeVivo: ...

It’s been a few years since we featured the company. So could you give us a brief history and some milestones for Aclarion? Mr. Ness: Certainly. We successfully completed an IPO in April of 2022. And ...